fashion -WSS

fashion

author：entertainment 2025-09-28 08:53:24 - browse：3743

Silhouette of a medical staff, followed by another, running pushing a nursing bed. Two people talk next to the hurrying staff in the corridor — coverage from STAT — Adobe

There’s ample evidence that private equity buyouts in health care drive up costs. A new study shows quality declines, too.

Hospitals acquired by private equity saw a 25% uptick in adverse events compared with controls, according to a new study released today in the Journal of the American Medical Association. The findings add to an accumulating body of literature underscoring the harm that occurs when financial investors take over health care providers — not only hospitals, but nursing homes, hospice care, and physician practices.

Even after adjusting their findings to be more conservative, the researchers on the JAMA study found that all of the hospital-acquired conditions they studied increased three years after a private equity acquisition compared to control hospitals. Not all of the increases were statistically significant.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： With psoriasis trial ahead, Alumis raises $259 million

WSS

Why depression after traumatic brain injury is distinct

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

How to save health care price transparency rules

HHS secretary Becerra pressed on Change HealthCare cyberattack

RSV shot was 90% effective at preventing hospitalizations in kids

leisure time

fashion

focus

Activists slam private health insurers over coverage restrictions

Why depression after traumatic brain injury is distinct

Duchenne breakthrough therapy leaves behind pioneering families

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Moonlake's readout produced a cash windfall. Risks remain

First U.S. drug developed to treat liver disease MASH is approved

Medical records are filled with copy

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Bristol, Sangamo, Gilead, and more

knowledge

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Amid AI frenzy, a top HHS official's quest to create safeguards

Boston's new lab space is opening empty

Novo Nordisk obesity pill bests Wegovy in early trial

Readout Newsletter: CAR

HHS secretary Becerra pressed on Change HealthCare cyberattack

focus

hotspot

Wikipedia

explore